[Pegasys: FDA approved Pegasys (peginterferon alfa-2a) for the treatment of hepatitis C].
Iafolla
Mauricio
M
D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D014481:United States; D014486:United States Food and Drug Administration
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a
Pegasys. La FDA aprobó Pegasys (peginterferon alfa-2a) para el tratamiento de la hepatitis C.